Mr. Hugh MacNaught reports

VENTRIPOINT APPOINTS NICOLAS COUTIN TO OVERSEE CLINICAL AFFAIRS

Ventripoint Diagnostics Ltd. has appointed Nic Coutin, PhD, to oversee clinical affairs. In this role he will be providing leadership to the company's continuing research, translational science and clinical studies. Dr. Coutin will report directly to Hugh MacNaught, president and chief executive officer.

Dr. Coutin was part of the partnering team at AbCellera which built industry-leading capabilities through partnerships with the top tier of biotech and pharma industry partners. His experience includes leading the venture and core programming team at Creative Destruction Lab, where, with his team, he delivered an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.

"Nic has experience and a strong understanding of translational programs," said Ventripoint's CEO, Hugh MacNaught. "His experience supporting the advancement of innovation from research to the clinic will enable us to build stronger relationships with our clinical advisers and collaborators."

Dr. Coutin added: "Ventripoint's decades of research and development have positioned it become the new standard for rapidly and robustly measuring heart function. Strengthening the clinical-evidence base will support broader clinical use of Ventripoint's VMS+ V4.0. I look forward to working with the team to expand the application of this differentiated technology to numerous cardiac indications."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.